| 2010 | Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial | LUNG CANCER |
| 2023 | Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
| JOURNAL OF THORACIC ONCOLOGY |
| 2020 | Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2020 | Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2023 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
| ONCOLOGIST |
| 2020 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD) | CLINICAL LUNG CANCER |
| 2009 | Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC | JOURNAL OF NEURO-ONCOLOGY |
| 2023 | Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
| JOURNAL OF THORACIC ONCOLOGY |
| 2021 | Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
| JTO Clinical and Research Reports |
| 2015 | Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy
| JOURNAL OF THORACIC ONCOLOGY |
| 2018 | Can We Prevent Resistance to Osimertinib? Combination or Sequential | JOURNAL OF THORACIC ONCOLOGY |
| 2009 | Cancer in Patients on Chronic Dialysis in Korea
| JOURNAL OF KOREAN MEDICAL SCIENCE |
| 2023 | Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
| NATURE COMMUNICATIONS |
| 2008 | Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2021 | Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies
| JTO Clinical and Research Reports |
| 2023 | Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis
| JOURNAL OF THORACIC ONCOLOGY |
| 2007 | Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy | ACTA ONCOLOGICA |
| 2018 | Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice | JOURNAL OF THORACIC ONCOLOGY |
| 2019 | Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity | HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK |
| 2008 | Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients
| BMC CANCER |
| 2004 | Clinical and echocardiographic characteristics of pericardial effusion in patients who underwent echocardiographically guided pericardiocentesis: Yonsei Cardiovascular Center experience, 1993-2003
| YONSEI MEDICAL JOURNAL |
| 2014 | Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma | LUNG CANCER |
| 2016 | Clinical course of stage IV invasive mucinous adenocarcinoma of the lung | LUNG CANCER |
| 2024 | Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific
| ORAL ONCOLOGY |
| 2021 | Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2023 | Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea
| Cancer Treatment and Research Communications |
| 2016 | Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. | LUNG CANCER |
| 2017 | Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma | ANNALS OF ONCOLOGY |
| 2022 | Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2020 | Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade | JCI INSIGHT |
| 2008 | Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Complete response of recurrent squamous cell carcinoma of the lung: dose the dose matter? | JOURNAL OF THORACIC ONCOLOGY |
| 2020 | Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2019 | Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
| JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2017 | Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
| ONCOTARGET |
| 2004 | Congenital absence of inferior vena cava as a rare cause of pulmonary thromboembolism
| YONSEI MEDICAL JOURNAL |
| 2022 | Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation
| THERANOSTICS |
| 2012 | Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer | NUCLEAR MEDICINE AND MOLECULAR IMAGING |
| 2020 | Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study | CLINICAL LUNG CANCER |
| 2017 | Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis
| ONCOTARGET |
| 2021 | DGG-100629 inhibits lung cancer growth by suppressing the NFATc1/DDIAS/STAT3 pathway
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2021 | Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
| CANCERS |
| 2012 | Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
| CANCER |
| 2022 | DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor-resistant lung cancer therapy
| EXPERIMENTAL AND MOLECULAR MEDICINE |
| 2010 | Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY |
| 2017 | Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy
| CANCER RESEARCH AND TREATMENT |
| 2019 | Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer | CANCER LETTERS |
| 2017 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2018 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study | LANCET ONCOLOGY |
| 2023 | Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2023 | Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial | JAMA ONCOLOGY |
| 2019 | Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy | LUNG CANCER |
| 2023 | Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA | CLINICAL CANCER RESEARCH |
| 2022 | Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience | CANCER IMMUNOLOGY IMMUNOTHERAPY |
| 2019 | Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2023 | Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
| CANCER RESEARCH AND TREATMENT |
| 2016 | Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study | CANCER |
| 2021 | Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
| JOURNAL OF THORACIC ONCOLOGY |
